Literature DB >> 8915314

Bleomycin-mediated electrochemotherapy of metastatic melanoma.

L F Glass1, M L Pepine, N A Fenske, M Jaroszeski, D S Reintgen, R Heller.   

Abstract

BACKGROUND: Electroporation is a new technique that enhances the antitumor effects of chemotherapy by exposing cancerous tissues to pulses of electricity. When used in combination with conventional chemotherapy, the procedure is termed electrochemotherapy (ECT). The electric pulses increase cell membrane permeability and thus intracellular access. Electrochemotherapy has been shown to have potent antitumor activity in a number of in vitro studies, several animal models, and clinical trials with squamous cell carcinomas and basal cell carcinomas.
OBJECTIVE: To report the effects of ECT in 5 patients with metastatic malignant melanoma.
RESULTS: Twenty-three lesions of metastatic melanoma were treated with intralesional bleomycin sulfate followed by pulses of electricity. Pulses were delivered via caliper or needle electrodes placed around the tumor. Complete responses were observed in 18 tumors (78%) and partial responses were seen in 4 (17%). No responses were seen in lesions treated with either pulses or bleomycin alone. Vital signs were closely monitored during the procedure, and minimal side effects were noted.
CONCLUSIONS: This is the first study that documents the antitumor effects of ECT in metastatic melanoma. Although not a cure, it may be an effective alternative to palliative surgery or irradiation in these patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915314

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  15 in total

1.  Induction of apoptosis of liver cancer cells by nanosecond pulsed electric fields (nsPEFs).

Authors:  Ling He; Deyou Xiao; Jianguo Feng; Chenguo Yao; Liling Tang
Journal:  Med Oncol       Date:  2017-01-06       Impact factor: 3.064

Review 2.  Electrochemotherapy in head and neck cancer: A review of an emerging cancer treatment.

Authors:  Armando De Virgilio; Massimo Ralli; Lucia Longo; Patrizia Mancini; Giuseppe Attanasio; Francesca Atturo; Marco De Vincentiis; Antonio Greco
Journal:  Oncol Lett       Date:  2018-07-12       Impact factor: 2.967

3.  Electrochemotherapy: aspects of preclinical development and early clinical experience.

Authors:  John O Larkin; Christopher G Collins; Simon Aarons; Mark Tangney; Maria Whelan; Seamus O'Reily; Oscar Breathnach; Declan M Soden; Gerald C O'Sullivan
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

Review 4.  [Electrochemotherapy of skin tumors].

Authors:  U Reinhold
Journal:  Hautarzt       Date:  2011-07       Impact factor: 0.751

Review 5.  Plasmid IL-12 electroporation in melanoma.

Authors:  Edward Cha; Adil Daud
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

6.  Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults.

Authors:  Mark Wallace; Barbara Evans; Sandra Woods; Robin Mogg; Lei Zhang; Adam C Finnefrock; Dietmar Rabussay; Michael Fons; John Mallee; Devan Mehrotra; Florian Schödel; Luwy Musey
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  Electroporation therapy in soft tissue sarcoma: a potentially effective novel treatment.

Authors:  Remco de Bree; Bernard M Tijink; Cees J van Groeningen; C René Leemans
Journal:  Sarcoma       Date:  2006

8.  Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields.

Authors:  H Sauer; V Pütz; K Fischer; J Hescheler; M Wartenberg
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

9.  Results of Dynamic Contrast-Enhanced Ultrasound Correlate With Treatment Outcome in Canine Neoplasia Treated With Electrochemotherapy and Interleukin-12 Plasmid Electrotransfer.

Authors:  Maja Brloznik; Simona Kranjc Brezar; Nina Boc; Tanja Knific; Maja Cemazar; Nina Milevoj; Gregor Sersa; Natasa Tozon; Darja Pavlin
Journal:  Front Vet Sci       Date:  2021-05-20

10.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.

Authors:  P Radny; U M Caroli; J Bauer; T Paul; C Schlegel; T K Eigentler; B Weide; M Schwarz; C Garbe
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.